182 related articles for article (PubMed ID: 32614159)
21. Regulatory T cell inhibition by dasatinib is associated with natural killer cell differentiation and a favorable molecular response-The final results of the D-first study.
Najima Y; Yoshida C; Iriyama N; Fujisawa S; Wakita H; Chiba S; Okamoto S; Kawakami K; Takezako N; Kumagai T; Ohyashiki K; Taguchi J; Yano S; Igarashi T; Kouzai Y; Morita S; Sakamoto J; Sakamaki H; Inokuchi K
Leuk Res; 2018 Mar; 66():66-72. PubMed ID: 29407585
[TBL] [Abstract][Full Text] [Related]
22. Importance of TKI treatment duration in treatment-free remission of chronic myeloid leukemia: results of the D-FREE study.
Yoshida C; Yamaguchi H; Doki N; Murai K; Iino M; Hatta Y; Onizuka M; Yokose N; Fujimaki K; Hagihara M; Oshikawa G; Murayama K; Kumagai T; Kimura S; Najima Y; Iriyama N; Tsutsumi I; Oba K; Kojima H; Sakamaki H; Inokuchi K;
Int J Hematol; 2023 May; 117(5):694-705. PubMed ID: 36739328
[TBL] [Abstract][Full Text] [Related]
23. In-depth characterization of NK cell markers from CML patients who discontinued tyrosine kinase inhibitor therapy.
Sanchez MB; Vasconcelos Cordoba B; Pavlovsky C; Moiraghi B; Varela A; Custidiano R; Fernandez I; Freitas MJ; Ventriglia MV; Bendek G; Mariano R; Mela Osorio MJ; Pavlovsky MA; García de Labanca A; Foncuberta C; Giere I; Vera M; Juni M; Mordoh J; Sanchez Avalos JC; Levy EM; Bianchini M
Front Immunol; 2023; 14():1241600. PubMed ID: 37818372
[TBL] [Abstract][Full Text] [Related]
24. Feasibility of the imatinib stop study in the Japanese clinical setting: delightedly overcome CML expert stop TKI trial (DOMEST Trial).
Fujisawa S; Ueda Y; Usuki K; Kobayashi H; Kondo E; Doki N; Nakao T; Kanda Y; Kosugi N; Kosugi H; Kumagai T; Harada H; Shikami M; Maeda Y; Sakura T; Inokuchi K; Saito A; Nawa Y; Ogasawara M; Nishida J; Kondo T; Yoshida C; Kuroda H; Tabe Y; Maeda Y; Imajo K; Kojima K; Morita S; Komukai S; Kawaguchi A; Sakamoto J; Kimura S
Int J Clin Oncol; 2019 Apr; 24(4):445-453. PubMed ID: 30421023
[TBL] [Abstract][Full Text] [Related]
25. Rapid and sustained increase of large granular lymphocytes and rare cytomegalovirus reactivation during dasatinib treatment in chronic myelogenous leukemia patients.
Tanaka H; Nakashima S; Usuda M
Int J Hematol; 2012 Sep; 96(3):308-19. PubMed ID: 22767140
[TBL] [Abstract][Full Text] [Related]
26. Successful treatment-free remission in chronic myeloid leukaemia and its association with reduced immune suppressors and increased natural killer cells.
Irani YD; Hughes A; Clarson J; Kok CH; Shanmuganathan N; White DL; Yeung DT; Ross DM; Hughes TP; Yong ASM
Br J Haematol; 2020 Nov; 191(3):433-441. PubMed ID: 32352166
[TBL] [Abstract][Full Text] [Related]
27. Treatment-free remission after dasatinib in patients with chronic myeloid leukaemia in chronic phase with deep molecular response: Final 5-year analysis of DASFREE.
Shah NP; García-Gutiérrez V; Jiménez-Velasco A; Larson SM; Saussele S; Rea D; Mahon FX; Levy MY; Gómez-Casares MT; Mauro MJ; Sy O; Martin-Regueira P; Lipton JH
Br J Haematol; 2023 Sep; 202(5):942-952. PubMed ID: 37246588
[TBL] [Abstract][Full Text] [Related]
28. Does the frequency of molecular monitoring after tyrosine kinase inhibitor discontinuation affect outcomes of patients with chronic myeloid leukemia?
Kong JH; Winton EF; Heffner LT; Chen Z; Langston AA; Hill B; Arellano M; El-Rassi F; Kim A; Jillella A; Kota VK; Bodó I; Khoury HJ
Cancer; 2017 Jul; 123(13):2482-2488. PubMed ID: 28241101
[TBL] [Abstract][Full Text] [Related]
29. Sustained treatment-free remission in chronic myeloid leukaemia is associated with an increased frequency of innate CD8(+) T-cells.
Cayssials E; Jacomet F; Piccirilli N; Lefèvre L; Roy L; Guilhot F; Chomel JC; Leleu X; Gombert JM; Herbelin A; Barbarin A
Br J Haematol; 2019 Jul; 186(1):54-59. PubMed ID: 30864168
[TBL] [Abstract][Full Text] [Related]
30. Effect of Age on NK Cell Compartment in Chronic Myeloid Leukemia Patients Treated With Tyrosine Kinase Inhibitors.
Rodrigues-Santos P; López-Sejas N; Almeida JS; Ruzičková L; Couceiro P; Alves V; Campos C; Alonso C; Tarazona R; Freitas-Tavares P; Solana R; Santos-Rosa M
Front Immunol; 2018; 9():2587. PubMed ID: 30487792
[TBL] [Abstract][Full Text] [Related]
31. Second tyrosine kinase inhibitor discontinuation attempt in patients with chronic myeloid leukemia.
Legros L; Nicolini FE; Etienne G; Rousselot P; Rea D; Giraudier S; Guerci-Bresler A; Huguet F; Gardembas M; Escoffre M; Ianotto JC; Noël MP; Varet BR; Pagliardini T; Touitou I; Morisset S; Mahon FX;
Cancer; 2017 Nov; 123(22):4403-4410. PubMed ID: 28743166
[TBL] [Abstract][Full Text] [Related]
32. Relative increase in lymphocytes from as early as 1 month predicts improved response to dasatinib in chronic-phase chronic myelogenous leukemia.
Kumagai T; Matsuki E; Inokuchi K; Ohashi K; Shinagawa A; Takeuchi J; Yoshida C; Okamoto S; Wakita H; Kozai Y; Shirasugi Y; Fujisawa S; Iwase O; Yano S; Nishiwaki K; Oba K; Sakamoto J; Sakamaki H
Int J Hematol; 2014 Jan; 99(1):41-52. PubMed ID: 24297450
[TBL] [Abstract][Full Text] [Related]
33. Association of TIM-3 checkpoint receptor expression on T cells with treatment-free remission in chronic myeloid leukemia.
Irani YD; Kok CH; Clarson J; Shanmuganathan N; Branford S; Yeung DT; Ross DM; Hughes TP; Yong ASM
Blood Adv; 2023 Jun; 7(11):2364-2374. PubMed ID: 36622326
[TBL] [Abstract][Full Text] [Related]
34. Immune modulation in chronic myeloid leukaemia patients treated with nilotinib and interferon-alpha.
Irani YD; Hughes A; Kok CH; Clarson J; Yeung DT; Ross DM; Branford S; Hughes TP; Yong ASM
Br J Haematol; 2023 Sep; 202(6):1127-1136. PubMed ID: 37482935
[TBL] [Abstract][Full Text] [Related]
35. Expansion of highly differentiated CD8+ T-cells or NK-cells in patients treated with dasatinib is associated with cytomegalovirus reactivation.
Kreutzman A; Ladell K; Koechel C; Gostick E; Ekblom M; Stenke L; Melo T; Einsele H; Porkka K; Price DA; Mustjoki S; Seggewiss R
Leukemia; 2011 Oct; 25(10):1587-97. PubMed ID: 21647156
[TBL] [Abstract][Full Text] [Related]
36. Sustained molecular response following a failed attempt of tyrosine kinase inhibitor discontinuation & the effects on growth in a child with chronic myeloid leukemia: not always a short story.
Triche L; Yarbrough A; Roth M; Ying A; Wells R
Pediatr Hematol Oncol; 2020 Aug; 37(5):375-379. PubMed ID: 32347770
[TBL] [Abstract][Full Text] [Related]
37. [Analysis the influence factors of treatment free remission outcome with chronic myeloid leukemia patients who discontinued tyrosine kinase inhibitors].
Zhao HF; Zhang Y; Dang LX; Liang JL; Chen SX; Guo Z; Li YL; Zu RR; Gui XD; Wei YP; Song Y
Zhonghua Yi Xue Za Zhi; 2022 May; 102(20):1523-1529. PubMed ID: 35692068
[No Abstract] [Full Text] [Related]
38. Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation.
Bernardi S; Malagola M; Zanaglio C; Polverelli N; Dereli Eke E; D'Adda M; Farina M; Bucelli C; Scaffidi L; Toffoletti E; Deambrogi C; Stagno F; Bergamaschi M; Franceschini L; Abruzzese E; Divona MD; Gobbi M; Di Raimondo F; Gaidano G; Tiribelli M; Bonifacio M; Cattaneo C; Iurlo A; Russo D
Cancer Med; 2019 May; 8(5):2041-2055. PubMed ID: 30950237
[TBL] [Abstract][Full Text] [Related]
39. Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: the DASFREE study.
Shah NP; García-Gutiérrez V; Jiménez-Velasco A; Larson S; Saussele S; Rea D; Mahon FX; Levy MY; Gómez-Casares MT; Pane F; Nicolini FE; Mauro MJ; Sy O; Martin-Regueira P; Lipton JH
Leuk Lymphoma; 2020 Mar; 61(3):650-659. PubMed ID: 31647335
[TBL] [Abstract][Full Text] [Related]
40. Clinical Efficacy and Safety of First-Line Dasatinib Therapy and the Relevance of Velocity of BCR-ABL1 Transcript Decline for Achievement of Molecular Responses in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Report from the Juntendo Yamanashi Cooperative Study Group.
Takaku T; Iriyama N; Mitsumori T; Sato E; Gotoh A; Kirito K; Noguchi M; Koike M; Sakamoto J; Oba K; Komatsu N
Oncology; 2018; 94(2):85-91. PubMed ID: 29151104
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]